Clinical aspects and management of AIDS-related Kaposi's sarcoma

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

AIDS-related Kaposi's sarcoma (KS) is a tumour of vascular endothelium, which is seen predominately in men who have sex with men. The majority of affected individuals have advanced immunosuppression at the time of the initial KS diagnosis. The disease may present with cutaneous lesions, or with involvement of visceral organs, of which the gastrointestinal tract is most common. KS may also present with lymphoadenopathy or with isolated lymphoedema, even in the absence of cutaneous lesions. Affected individuals are uniformly co-infected with HIV and with Human Herpesvirus type 8 (HHV8). HHV8 is present within KS tissues, and is aetiological in the pathogenesis of disease, along with aberrant cytokine expression, production of multiple angiogenic peptides, and immune dysregulation. While not presently curable, multiple treatment options exist and must be evaluated in terms of the specific needs of the individual patient. Various local therapies are aimed at eradicating small lesions, while acknowledging that the KS in general, or its likelihood of recurring will be unaffected. Systemic chemotherapy is used to treat extensive visceral involvement. Knowledge of the pathogenesis of disease has led to the development of novel treatment strategies, aimed at HHV8 as the target of therapy, or at the inflammatory cytokine or angiogenic milieu necessary for KS growth. Use of highly active anti-retroviral therapy, aimed at controlling the underlying HIV infection, has been associated with a dramatic decrease in the incidence of KS, and may also be useful in the treatment of existing KS disease.

Original languageEnglish (US)
Pages (from-to)1288-1295
Number of pages8
JournalEuropean Journal of Cancer
Volume37
Issue number10
DOIs
StatePublished - 2001

Fingerprint

Kaposi's Sarcoma
Human Herpesvirus 8
Therapeutics
Angiogenic Proteins
Cytokines
Xeroderma Pigmentosum
Skin
Lymphedema
Vascular Endothelium
AIDS-related Kaposi sarcoma
Immunosuppression
HIV Infections
Gastrointestinal Tract
HIV
Drug Therapy
Incidence
Growth
Neoplasms

Keywords

  • AIDS
  • AIDS malignancies
  • AIDS-KS
  • Kaposi's sarcoma
  • Therapy for AIDS-KS
  • Treatment of KS

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Clinical aspects and management of AIDS-related Kaposi's sarcoma. / Sparano, Joseph A.

In: European Journal of Cancer, Vol. 37, No. 10, 2001, p. 1288-1295.

Research output: Contribution to journalArticle

@article{74d10f0f95084ba6a5e35c0830c2229f,
title = "Clinical aspects and management of AIDS-related Kaposi's sarcoma",
abstract = "AIDS-related Kaposi's sarcoma (KS) is a tumour of vascular endothelium, which is seen predominately in men who have sex with men. The majority of affected individuals have advanced immunosuppression at the time of the initial KS diagnosis. The disease may present with cutaneous lesions, or with involvement of visceral organs, of which the gastrointestinal tract is most common. KS may also present with lymphoadenopathy or with isolated lymphoedema, even in the absence of cutaneous lesions. Affected individuals are uniformly co-infected with HIV and with Human Herpesvirus type 8 (HHV8). HHV8 is present within KS tissues, and is aetiological in the pathogenesis of disease, along with aberrant cytokine expression, production of multiple angiogenic peptides, and immune dysregulation. While not presently curable, multiple treatment options exist and must be evaluated in terms of the specific needs of the individual patient. Various local therapies are aimed at eradicating small lesions, while acknowledging that the KS in general, or its likelihood of recurring will be unaffected. Systemic chemotherapy is used to treat extensive visceral involvement. Knowledge of the pathogenesis of disease has led to the development of novel treatment strategies, aimed at HHV8 as the target of therapy, or at the inflammatory cytokine or angiogenic milieu necessary for KS growth. Use of highly active anti-retroviral therapy, aimed at controlling the underlying HIV infection, has been associated with a dramatic decrease in the incidence of KS, and may also be useful in the treatment of existing KS disease.",
keywords = "AIDS, AIDS malignancies, AIDS-KS, Kaposi's sarcoma, Therapy for AIDS-KS, Treatment of KS",
author = "Sparano, {Joseph A.}",
year = "2001",
doi = "10.1016/S0959-8049(01)00109-5",
language = "English (US)",
volume = "37",
pages = "1288--1295",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Clinical aspects and management of AIDS-related Kaposi's sarcoma

AU - Sparano, Joseph A.

PY - 2001

Y1 - 2001

N2 - AIDS-related Kaposi's sarcoma (KS) is a tumour of vascular endothelium, which is seen predominately in men who have sex with men. The majority of affected individuals have advanced immunosuppression at the time of the initial KS diagnosis. The disease may present with cutaneous lesions, or with involvement of visceral organs, of which the gastrointestinal tract is most common. KS may also present with lymphoadenopathy or with isolated lymphoedema, even in the absence of cutaneous lesions. Affected individuals are uniformly co-infected with HIV and with Human Herpesvirus type 8 (HHV8). HHV8 is present within KS tissues, and is aetiological in the pathogenesis of disease, along with aberrant cytokine expression, production of multiple angiogenic peptides, and immune dysregulation. While not presently curable, multiple treatment options exist and must be evaluated in terms of the specific needs of the individual patient. Various local therapies are aimed at eradicating small lesions, while acknowledging that the KS in general, or its likelihood of recurring will be unaffected. Systemic chemotherapy is used to treat extensive visceral involvement. Knowledge of the pathogenesis of disease has led to the development of novel treatment strategies, aimed at HHV8 as the target of therapy, or at the inflammatory cytokine or angiogenic milieu necessary for KS growth. Use of highly active anti-retroviral therapy, aimed at controlling the underlying HIV infection, has been associated with a dramatic decrease in the incidence of KS, and may also be useful in the treatment of existing KS disease.

AB - AIDS-related Kaposi's sarcoma (KS) is a tumour of vascular endothelium, which is seen predominately in men who have sex with men. The majority of affected individuals have advanced immunosuppression at the time of the initial KS diagnosis. The disease may present with cutaneous lesions, or with involvement of visceral organs, of which the gastrointestinal tract is most common. KS may also present with lymphoadenopathy or with isolated lymphoedema, even in the absence of cutaneous lesions. Affected individuals are uniformly co-infected with HIV and with Human Herpesvirus type 8 (HHV8). HHV8 is present within KS tissues, and is aetiological in the pathogenesis of disease, along with aberrant cytokine expression, production of multiple angiogenic peptides, and immune dysregulation. While not presently curable, multiple treatment options exist and must be evaluated in terms of the specific needs of the individual patient. Various local therapies are aimed at eradicating small lesions, while acknowledging that the KS in general, or its likelihood of recurring will be unaffected. Systemic chemotherapy is used to treat extensive visceral involvement. Knowledge of the pathogenesis of disease has led to the development of novel treatment strategies, aimed at HHV8 as the target of therapy, or at the inflammatory cytokine or angiogenic milieu necessary for KS growth. Use of highly active anti-retroviral therapy, aimed at controlling the underlying HIV infection, has been associated with a dramatic decrease in the incidence of KS, and may also be useful in the treatment of existing KS disease.

KW - AIDS

KW - AIDS malignancies

KW - AIDS-KS

KW - Kaposi's sarcoma

KW - Therapy for AIDS-KS

KW - Treatment of KS

UR - http://www.scopus.com/inward/record.url?scp=0034968659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034968659&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(01)00109-5

DO - 10.1016/S0959-8049(01)00109-5

M3 - Article

VL - 37

SP - 1288

EP - 1295

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -